Stockscreener 앱 받기
27.93
2.84%
0.8069
전일 마감가:
$27.12
열려 있는:
$27.54
하루 거래량:
1.43M
Relative Volume:
0.71
시가총액:
$4.44B
수익:
$264.79M
순이익/손실:
$-14.36M
주가수익비율:
-253.88
EPS:
-0.11
순현금흐름:
$-28.11M
1주 성능:
+0.69%
1개월 성능:
-24.79%
6개월 성능:
-9.24%
1년 성능:
+31.37%
1일 변동 폭
$27.22
$28.01
1주일 범위
$25.28
$28.88
52주 변동 폭
$20.39
$46.48
TG테라퓨틱스사 Stock (TGTX) Company Profile
명칭
Tg Therapeutics Inc
전화
(212) 554-4484
주소
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
TGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
27.95 | 4.19B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.64 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.25 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.09 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.33 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
TG테라퓨틱스사 Stock (TGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2024-10-29 | 개시 | TD Cowen | Buy |
| 2023-08-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2023-06-26 | 재개 | Jefferies | Buy |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-01 | 개시 | JP Morgan | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 개시 | Evercore ISI | Outperform |
| 2020-01-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2018-09-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 재개 | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 재개 | H.C. Wainwright | Buy |
| 2017-04-25 | 개시 | Jefferies | Buy |
| 2017-03-06 | 재확인 | FBR & Co. | Outperform |
| 2016-10-06 | 재개 | Brean Capital | Buy |
| 2016-05-27 | 개시 | SunTrust | Buy |
| 2015-12-01 | 개시 | FBR Capital | Outperform |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-08-12 | 재개 | H.C. Wainwright | Buy |
| 2015-06-19 | 재확인 | Brean Capital | Buy |
| 2014-12-11 | 재확인 | ROTH Capital | Buy |
| 2014-12-10 | 재확인 | ROTH Capital | Buy |
모두보기
TG테라퓨틱스사 주식(TGTX)의 최신 뉴스
How Investors Are Reacting To TG Therapeutics (TGTX) Raising 2025 Revenue Guidance After Strong Q2 Results - simplywall.st
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
TG Therapeutics Faces Regulatory and Legal Challenges Amid AI Risks - AInvest
Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges - The Globe and Mail
TG Therapeutics Faces Regulatory and Legal Risks with AI Integration - AInvest
TG Therapeutics Boosts Financial Strength with New Securities Filing - AInvest
TG Therapeutics Inc's Financial Performance and Strategic Positioning - AInvest
Willdan Group's Price Target Raised by Wedbush to $120, Up 41.18% - AInvest
Tg Therapeutics 2025 Q2 Earnings Net Income Surges 309.8% - AInvest
TG Therapeutics: Strategic Capital Flexibility Fuels Briumvi's Global Expansion and R&D Momentum - AInvest
TG THERAPEUTICS, INC. SEC 10-Q Report - TradingView
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline - MSN
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
TG Therapeutics falls after Q2 miss despite guidance raise - MSN
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript - Insider Monkey
TR | OpenAI4o Maintains TG Therapeutics(TGTX.US) With Hold Rating, Cuts Target Price to $30 - 富途牛牛
TGTX Stock Falls 14.1% Amid Market Volatility - AInvest
TGTX Raises FY25 Revenue Projection, BRIUMVI Target Increased - AInvest
TG Therapeutics’ Earnings Call Highlights BRIUMVI Success - TipRanks
Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment. - AInvest
TGTX Down As Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - Barchart.com
New Lantern Expands AI Radiology Platform with Mammography and PET/CT Viewers - AInvest
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates - MSN
TG Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
TG Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Rob - GuruFocus
TG Therapeutics: Q2 Earnings Snapshot - Connecticut Post
TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales - TipRanks
TG Therapeutics Stock Plunges 17.99% on Missed Earnings Despite Strong Revenue Surging Trading Volume Ranks 325th in Market Activity - AInvest
Update: TG Therapeutics Shares Fall After Q2 Earnings Miss Expectations - 富途牛牛
Investor Calendar Invites You to the TG Therapeutics, Inc First Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday May 10, 2016 - ACCESS Newswire
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook - Investor's Business Daily
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
TG Therapeutics stock falls despite in-line Briumvi sales as BofA reiterates Underperform - Investing.com India
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - Stocktwits
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - Benzinga
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN
Why Is TG Therapeutics Stock Falling Monday?TG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics Q2 Revenue Up 91% - The Motley Fool
TG Therapeutics Q2 Revenue Up 91% - Nasdaq
TG Therapeutics: Strong Market Position and Growth Prospects Make It an Attractive Buy - TipRanks
TG Therapeutics Q2 2025: Unpacking Contradictions in Market Share, Subcutaneous Trials, and Payer Demand Trends - AInvest
TG Therapeutics Plunges 15.76%—Is the Earnings Miss Just the Beginning? - AInvest
TG Therapeutics and BRIUMVI: A Deep Dive into Accelerating Revenue and Strategic Expansion in the MS Market - AInvest
Earnings call transcript: TG Therapeutics Q2 2025 misses EPS, raises revenue - Investing.com UK
TG Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TG Therapeutics Raises Outlook As BRIUMVI Sales Climb - Finimize
TG Therapeutics Reports Q2 Profit, Misses Wall Street ExpectationsNews and Statistics - IndexBox
TG테라퓨틱스사 (TGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
0.07%
자본화:
|
볼륨(24시간):